NO20005131L - Nye behandlinger for nervøse forstyrrelser - Google Patents

Nye behandlinger for nervøse forstyrrelser

Info

Publication number
NO20005131L
NO20005131L NO20005131A NO20005131A NO20005131L NO 20005131 L NO20005131 L NO 20005131L NO 20005131 A NO20005131 A NO 20005131A NO 20005131 A NO20005131 A NO 20005131A NO 20005131 L NO20005131 L NO 20005131L
Authority
NO
Norway
Prior art keywords
new treatments
nervous disorders
reboxetine
ocd
obsessive
Prior art date
Application number
NO20005131A
Other languages
English (en)
Other versions
NO20005131D0 (no
Inventor
Adriana Dubini
John Michael Mccall
Duncan Paul Taylor
Philip F Von Voigtlander
Erik Ho Fong Wong
Original Assignee
Pharmacia & Upjohn Spa
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa, Upjohn Co filed Critical Pharmacia & Upjohn Spa
Publication of NO20005131D0 publication Critical patent/NO20005131D0/no
Publication of NO20005131L publication Critical patent/NO20005131L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Mobile Radio Communication Systems (AREA)

Abstract

Denne patentsøknad beskriver behandlingen av tvangstanke-tvangshandlingsforstyrrelser (OCD) og panikklidelse (PD), omfattende administrering av en terapeutisk effektiv, ikke-toksisk dose av reboxetin og derivater og/eller farmasøytisk akseptable salter derav til en pasient.
NO20005131A 1998-04-13 2000-10-12 Nye behandlinger for nervøse forstyrrelser NO20005131L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8163298P 1998-04-13 1998-04-13
IT98MI000870 IT1305322B1 (it) 1998-04-23 1998-04-23 Uso di reboxetina per il trattamento di disturbi nervosi
US8503398P 1998-05-11 1998-05-11
PCT/US1999/004288 WO1999052518A2 (en) 1998-04-13 1999-04-02 New treatments for nervous disorders

Publications (2)

Publication Number Publication Date
NO20005131D0 NO20005131D0 (no) 2000-10-12
NO20005131L true NO20005131L (no) 2000-10-12

Family

ID=11379879

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005131A NO20005131L (no) 1998-04-13 2000-10-12 Nye behandlinger for nervøse forstyrrelser

Country Status (25)

Country Link
US (1) US6391876B1 (no)
EP (1) EP1071418B1 (no)
JP (1) JP2002511408A (no)
KR (1) KR100555279B1 (no)
CN (1) CN1197569C (no)
AT (1) ATE277617T1 (no)
AU (1) AU755612B2 (no)
BR (1) BR9909476A (no)
CA (1) CA2320722A1 (no)
DE (1) DE69920679T2 (no)
DK (1) DK1071418T3 (no)
EA (1) EA003546B1 (no)
ES (1) ES2228035T3 (no)
HU (1) HUP0101748A3 (no)
IL (1) IL138887A0 (no)
IT (1) IT1305322B1 (no)
NO (1) NO20005131L (no)
NZ (1) NZ507693A (no)
PL (1) PL194039B1 (no)
PT (1) PT1071418E (no)
SI (1) SI1071418T1 (no)
SK (1) SK14482000A3 (no)
TR (1) TR200002970T2 (no)
WO (1) WO1999052518A2 (no)
ZA (1) ZA200004480B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500827B2 (en) * 1998-05-08 2002-12-31 Pharmacia & Upjohn Company Drug combinations
EP1459750B1 (en) * 1999-07-01 2005-06-01 Pharmacia & Upjohn Company LLC (S,S)-reboxetine for treating fibromyalgia and other somatoform disorders
DE60035232T2 (de) 1999-07-01 2008-02-14 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom
PL366119A1 (en) * 2000-11-15 2005-01-24 Eli Lilly And Company Treatment of anxiety disorders
DE60328787D1 (de) * 2002-06-17 2009-09-24 Pfizer Italia Srl Pharmazeutische salze von reboxetin
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
GB8419683D0 (en) 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
GB2167407B (en) * 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
WO1999020279A1 (en) * 1997-10-17 1999-04-29 Eli Lilly And Company Potentiation of pharmaceuticals

Also Published As

Publication number Publication date
TR200002970T2 (tr) 2001-01-22
NZ507693A (en) 2003-08-29
NO20005131D0 (no) 2000-10-12
CN1197569C (zh) 2005-04-20
DK1071418T3 (da) 2005-01-03
SI1071418T1 (en) 2005-04-30
KR100555279B1 (ko) 2006-03-03
US6391876B1 (en) 2002-05-21
CN1293569A (zh) 2001-05-02
DE69920679T2 (de) 2006-03-02
KR20010042641A (ko) 2001-05-25
ZA200004480B (en) 2002-04-24
CA2320722A1 (en) 1999-10-21
AU3635199A (en) 1999-11-01
BR9909476A (pt) 2000-12-19
EA200001058A1 (ru) 2001-04-23
AU755612B2 (en) 2002-12-19
PL194039B1 (pl) 2007-04-30
ATE277617T1 (de) 2004-10-15
PT1071418E (pt) 2004-12-31
IL138887A0 (en) 2001-11-25
WO1999052518A3 (en) 1999-12-02
SK14482000A3 (sk) 2001-08-06
EA003546B1 (ru) 2003-06-26
EP1071418A2 (en) 2001-01-31
ES2228035T3 (es) 2005-04-01
WO1999052518A2 (en) 1999-10-21
HUP0101748A3 (en) 2001-12-28
ITMI980870A1 (it) 1999-10-23
DE69920679D1 (de) 2004-11-04
JP2002511408A (ja) 2002-04-16
HUP0101748A2 (hu) 2001-11-28
IT1305322B1 (it) 2001-05-04
PL346294A1 (en) 2002-01-28
EP1071418B1 (en) 2004-09-29

Similar Documents

Publication Publication Date Title
CA2375908A1 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
IL178745A0 (en) Methods for treatment and management of scleroderma using 4-(amino)-2(2,6-dioxo(3-piperidyl))-isoindoline -1,3-dione
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
KR960703009A (ko) 중추유래의 수면성 무호흡증 및 호흡곤란증의 치료를 위한 모다피닐의 사용
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
EE200200107A (et) Kiire algtoimega selektiivse serotoniini tagasihaaramise inhibiitori kasutamine ravimi valmistamiseks, mis on ette nähtud seksuaalse funktsioonihäireravimiseks
NO20052420L (no) Farmakologisk behandling av sovnapn±.
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
WO2004105690A3 (en) Treatment of chronic pain associated with drug or radiation therapy
NO20005131L (no) Nye behandlinger for nervøse forstyrrelser
NO20005059D0 (no) Nye behandlinger for nervøse lidelser
WO2000076500A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
MXPA04001805A (es) Nueva forma de dosificacion oral de liberacion prolongada.
NO984651L (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
BR0311180A (pt) Métodos para o tratamento de doenças e condições respiratórias utilizando um inibidor seletivo da inos
WO2002043566A3 (en) Devices and methods for treating low blood sugar levels
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
SE9803732D0 (sv) Nicotine treatment for obsessive compulsive disorder
MXPA04001812A (es) Nueva forma de dosificacion oral de liberacion prolongada.
RU2000106699A (ru) Способ лечения заболеваний методом настройки биоритмов организма
CA2532330A1 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
MXPA03010920A (es) Uso de alconil l- carnitina para preparacion de medicamento para tratar anhedonia.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application